Daniel Mayer
Research Subjects
Daniel Mayer has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Aharon E. Sareli
Department of Critical Care Medicine, Memorial Regional Hospital, Memorial Healthcare System, Hollywood , Florida, United States
3 shared publications - Alvaro Visbal
Department of Critical Care Medicine, Memorial Regional Hospital, Memorial Healthcare System, Hollywood , Florida, United States
3 shared publications - Candice Sareli
Office of Human Research, Memorial Healthcare System, Hollywood, FL 33021, USA
3 shared publications - Jianli Niu
Memorial Healthcare System
3 shared publications - Myeongji Kim
Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA
2 shared publications - Paula Andrea Eckardt
Memorial Healthcare System
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Critical Care
- Vol. 2026 (1) , 6192253
Reviving the Standstill Heart: Multimodal Management of Refractory Cardiac Arrest due to Massive Pulmonary Embolism
Introduction: Massive pulmonary embolism (PE) is a life‐threatening condition frequently associated with right ventricular (RV) strain, hypotension, and cardiac arrest. Recommended management includes IV alteplase for high‐risk PE. However, evidence guiding higher thrombolytic doses during cardiac arrest remains limited and is rarely reported. We present a case of massive PE requiring an atypically high cumulative tPA dose administered during CPR, resulting in return of spontaneous circulation (ROSC). Case Description: A 38‐year‐old female with prior DVT and PE presented with syncope and left lower extremity edema. Imaging confirmed bilateral PE and DVT. She was found to be hemodynamically unstable and was treated with 100 mg IV tPA. This resulted in transient improvement, but she subsequently suffered a prolonged PEA arrest. During ACLS, there was confirmation of cardiac standstill on POCUS. A second bolus of 50 mg tPA was administered 29 min into the code, which led to sustained ROSC within 2 min. Despite maximal vasopressor and inotropic support, persistent shock and hypoxemia necessitated pulmonary angiography and attempted thrombectomy, which was aborted due to recurrent arrest. Catheter‐directed thrombolysis with bilateral EKOS catheters was initiated, and by ICU Day 3, echocardiography revealed normalized RV function. Discussion: Massive PE causes acute RV failure and impaired pulmonary perfusion, which may limit thrombolytic delivery. Repeat tPA dosing during CPR may enhance clot penetration and improve outcomes. When systemic thrombolysis is insufficient, catheter‐directed therapies can provide additional hemodynamic benefit. Adjunctive strategies including ventilatory optimization, pulmonary vasodilation, and neuroprotection were critical for the patient to achieving full recovery. Conclusion: Aggressive, multidisciplinary management, including repeat thrombolysis during arrest, can overcome traditionally poor prognostic indicators in massive PE and result in favorable neurologic outcomes.
- 1 January 2026
- Published by Wiley in Case Reports in Critical Care
- Vol. 2026 (1) , 6192253
Open AccessReviving the Standstill Heart: Multimodal Management of Refractory Cardiac Arrest due to Massive Pulmonary Embolism
Introduction: Massive pulmonary embolism (PE) is a life‐threatening condition frequently associated with right ventricular (RV) strain, hypotension, and cardiac arrest. Recommended management includes IV alteplase for high‐risk PE. However, evidence guiding higher thrombolytic doses during cardiac arrest remains limited and is rarely reported. We present a case of massive PE requiring an atypically high cumulative tPA dose administered during CPR, resulting in return of spontaneous circulation (ROSC). Case Description: A 38‐year‐old female with prior DVT and PE presented with syncope and left lower extremity edema. Imaging confirmed bilateral PE and DVT. She was found to be hemodynamically unstable and was treated with 100 mg IV tPA. This resulted in transient improvement, but she subsequently suffered a prolonged PEA arrest. During ACLS, there was confirmation of cardiac standstill on POCUS. A second bolus of 50 mg tPA was administered 29 min into the code, which led to sustained ROSC within 2 min. Despite maximal vasopressor and inotropic support, persistent shock and hypoxemia necessitated pulmonary angiography and attempted thrombectomy, which was aborted due to recurrent arrest. Catheter‐directed thrombolysis with bilateral EKOS catheters was initiated, and by ICU Day 3, echocardiography revealed normalized RV function. Discussion: Massive PE causes acute RV failure and impaired pulmonary perfusion, which may limit thrombolytic delivery. Repeat tPA dosing during CPR may enhance clot penetration and improve outcomes. When systemic thrombolysis is insufficient, catheter‐directed therapies can provide additional hemodynamic benefit. Adjunctive strategies including ventilatory optimization, pulmonary vasodilation, and neuroprotection were critical for the patient to achieving full recovery. Conclusion: Aggressive, multidisciplinary management, including repeat thrombolysis during arrest, can overcome traditionally poor prognostic indicators in massive PE and result in favorable neurologic outcomes.
- 11 October 2023
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 193 (2) , 285-295
Clinical Features and Outcomes of Hospitalized Adult Patients With Breakthrough COVID-19 Infections: A Propensity-Score–Matched Observational Study
This study aimed to evaluate the impact of vaccination on ICU admission and in-hospital mortality among breakthrough COVID-19 infections. A total of 3351 adult patients hospitalized with COVID-19 in Memorial Healthcare System from June 1−September 20, 2021, were included, of whom 284 (8.5%) were fully vaccinated. A propensity score-matched analysis was conducted to compare fully vaccinated patients to controls who were not vaccinated. Propensity scores were calculated based on variables associated with vaccination status. A 1:1 matching ratio was applied using logistic regression models, ensuring balanced characteristics between the two groups. The matched samples were then subjected to multivariate analysis. Among breakthrough infections, vaccinated patients demonstrated lower incidences of ICU admission (10.3% vs. 16.4%, P = .042) and death (12.2% vs. 18.7%, P = .041) compared to the matched controls. Risk-adjusted multivariate analysis demonstrated a significant inverse association between vaccination and ICU admission (OR = 0.52, 95% CI 0.31–0.89; P = .019) as well as in-hospital mortality (OR = 0.57, 95% CI 0.34–0.94; P = .027). Vaccinated individuals experiencing breakthrough infections had significantly lower risks of ICU admission and in-hospital mortality. The findings highlight the benefits of COVID-19 vaccines in reducing severe outcomes in patients with breakthrough infections.
- 11 October 2023
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 193 (2) , 285-295
Clinical Features and Outcomes of Hospitalized Adult Patients With Breakthrough COVID-19 Infections: A Propensity-Score–Matched Observational Study
This study aimed to evaluate the impact of vaccination on ICU admission and in-hospital mortality among breakthrough COVID-19 infections. A total of 3351 adult patients hospitalized with COVID-19 in Memorial Healthcare System from June 1−September 20, 2021, were included, of whom 284 (8.5%) were fully vaccinated. A propensity score-matched analysis was conducted to compare fully vaccinated patients to controls who were not vaccinated. Propensity scores were calculated based on variables associated with vaccination status. A 1:1 matching ratio was applied using logistic regression models, ensuring balanced characteristics between the two groups. The matched samples were then subjected to multivariate analysis. Among breakthrough infections, vaccinated patients demonstrated lower incidences of ICU admission (10.3% vs. 16.4%, P = .042) and death (12.2% vs. 18.7%, P = .041) compared to the matched controls. Risk-adjusted multivariate analysis demonstrated a significant inverse association between vaccination and ICU admission (OR = 0.52, 95% CI 0.31–0.89; P = .019) as well as in-hospital mortality (OR = 0.57, 95% CI 0.34–0.94; P = .027). Vaccinated individuals experiencing breakthrough infections had significantly lower risks of ICU admission and in-hospital mortality. The findings highlight the benefits of COVID-19 vaccines in reducing severe outcomes in patients with breakthrough infections.
- Open Access
- 10 June 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (12) , 1703
Distinct Clinical Presentations and Outcomes of Hospitalized Adults with the SARS-CoV-2 Infection Occurring during the Omicron Variant Surge
The COVID-19 Omicron variant has imposed a tremendous burden on healthcare services. We characterized the types of the Omicron variant-associated hospitalizations and their associations with clinical outcomes. Consecutive adults hospitalized with COVID-19 during the Omicron variant surge period of 1–14 January 2022, were classified into one of three groups based on their clinical presentations on admission: Group 1—primary COVID-19; Group 2—extrapulmonary manifestations of COVID-19; and Group 3—incidental COVID-19. Of the 500 patients who were hospitalized, 51.4% fell into Group 1, 16.4% into Group 2, and 32.2% into Group 3. The patients in Groups 1 and 2 were older, with higher proportions of comorbidities than patients in Group 3. The Group 1 patients had the highest mortality rate (15.6%), followed by Group 2 (8.5%), and Group 3 (0.6%), with adjusted odds ratios (OR) of 22.65 (95% confidence interval [CI], 2.75–239.46; p = 0.004) and 10.95 (95% CI, 1.02–117.28; p = 0.048), respectively, compared to Group 3. Those in Group 1 showed a greater utilization of intensive care services (15.9%), followed by Group 2 (10.9%), and Group 3 (2.5%), with adjusted ORs of 7.95 (95% CI, 2.52–25.08; p < 0.001) and 5.07 (95% CI, 1.34–19.15; p = 0.017), respectively, compared to Group 3. The patients in Groups 1 and 2 had longer hospitalization stays than the patients in Group 3 (p < 0.001 and p = 0.002, respectively). Older age (≥65 years) was an independent factor associated with longer hospital stays (OR = 1.72, 95% CI, 1.07–2.77). These findings can help hospitals prioritize patient care and service planning for future SARS-CoV-2 variants.
- 10 June 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (12) , 1703
Open AccessDistinct Clinical Presentations and Outcomes of Hospitalized Adults with the SARS-CoV-2 Infection Occurring during the Omicron Variant Surge
The COVID-19 Omicron variant has imposed a tremendous burden on healthcare services. We characterized the types of the Omicron variant-associated hospitalizations and their associations with clinical outcomes. Consecutive adults hospitalized with COVID-19 during the Omicron variant surge period of 1–14 January 2022, were classified into one of three groups based on their clinical presentations on admission: Group 1—primary COVID-19; Group 2—extrapulmonary manifestations of COVID-19; and Group 3—incidental COVID-19. Of the 500 patients who were hospitalized, 51.4% fell into Group 1, 16.4% into Group 2, and 32.2% into Group 3. The patients in Groups 1 and 2 were older, with higher proportions of comorbidities than patients in Group 3. The Group 1 patients had the highest mortality rate (15.6%), followed by Group 2 (8.5%), and Group 3 (0.6%), with adjusted odds ratios (OR) of 22.65 (95% confidence interval [CI], 2.75–239.46; p = 0.004) and 10.95 (95% CI, 1.02–117.28; p = 0.048), respectively, compared to Group 3. Those in Group 1 showed a greater utilization of intensive care services (15.9%), followed by Group 2 (10.9%), and Group 3 (2.5%), with adjusted ORs of 7.95 (95% CI, 2.52–25.08; p < 0.001) and 5.07 (95% CI, 1.34–19.15; p = 0.017), respectively, compared to Group 3. The patients in Groups 1 and 2 had longer hospitalization stays than the patients in Group 3 (p < 0.001 and p = 0.002, respectively). Older age (≥65 years) was an independent factor associated with longer hospital stays (OR = 1.72, 95% CI, 1.07–2.77). These findings can help hospitals prioritize patient care and service planning for future SARS-CoV-2 variants.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Endocrine Surgery
- Vol. 23 (2) , 59-63
A Case Report of Severe Tracheal Compression Secondary to a Large Benign Substernal Goiter
Kim M, et al. J Endocr Surg. 2023 Jun;23(2):59-63. https://doi.org/10.16956/jes.2023.23.2.59
- 1 January 2023
- Published by XMLink in Journal of Endocrine Surgery
- Vol. 23 (2) , 59-63
Open AccessA Case Report of Severe Tracheal Compression Secondary to a Large Benign Substernal Goiter
Kim M, et al. J Endocr Surg. 2023 Jun;23(2):59-63. https://doi.org/10.16956/jes.2023.23.2.59
- Open Access
- 28 January 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (3) , 700
Lymphopenia as a Predictor for Adverse Clinical Outcomes in Hospitalized Patients with COVID-19: A Single Center Retrospective Study of 4485 Cases
Lymphopenia is commonly present in patients with COVID-19. We sought to determine if lymphopenia on admission predicts COVID-19 clinical outcomes. A retrospective chart review was performed on 4485 patients with laboratory-confirmed COVID-19, who were admitted to the hospital. Of those, 2409 (57.3%) patients presented with lymphopenia (absolute lymphocyte count < 1.1 × 109/L) on admission, and had higher incidences of ICU admission (17.9% versus 9.5%, p < 0.001), invasive mechanical ventilation (14.4% versus 6.5%, p < 0.001), dialysis (3.4% versus 1.8%, p < 0.001) and in-hospital mortality (16.6% versus 6.6%, p < 0.001), with multivariable-adjusted odds ratios of 1.86 (95% confidence interval [CI], 1.55–2.25), 2.09 (95% CI, 1.69–2.59), 1.77 (95% CI, 1.19–2.68), and 2.19 (95% CI 1.76–2.72) for the corresponding outcomes, respectively, compared to those without lymphopenia. The restricted cubic spline models showed a non-linear relationship between lymphocyte count and adverse outcomes, with an increase in the risk of adverse outcomes for lower lymphocyte counts in patients with lymphopenia. The predictive powers of lymphopenia, expressed as areas under the receiver operating characteristic curves, were 0.68, 0.69, 0.78, and 0.79 for the corresponding adverse outcomes, respectively, after incorporating age, gender, race, and comorbidities. In conclusion, lymphopenia is a useful metric in prognosticating outcomes in hospitalized COVID-19 patients.
- 28 January 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (3) , 700
Open AccessLymphopenia as a Predictor for Adverse Clinical Outcomes in Hospitalized Patients with COVID-19: A Single Center Retrospective Study of 4485 Cases
Lymphopenia is commonly present in patients with COVID-19. We sought to determine if lymphopenia on admission predicts COVID-19 clinical outcomes. A retrospective chart review was performed on 4485 patients with laboratory-confirmed COVID-19, who were admitted to the hospital. Of those, 2409 (57.3%) patients presented with lymphopenia (absolute lymphocyte count < 1.1 × 109/L) on admission, and had higher incidences of ICU admission (17.9% versus 9.5%, p < 0.001), invasive mechanical ventilation (14.4% versus 6.5%, p < 0.001), dialysis (3.4% versus 1.8%, p < 0.001) and in-hospital mortality (16.6% versus 6.6%, p < 0.001), with multivariable-adjusted odds ratios of 1.86 (95% confidence interval [CI], 1.55–2.25), 2.09 (95% CI, 1.69–2.59), 1.77 (95% CI, 1.19–2.68), and 2.19 (95% CI 1.76–2.72) for the corresponding outcomes, respectively, compared to those without lymphopenia. The restricted cubic spline models showed a non-linear relationship between lymphocyte count and adverse outcomes, with an increase in the risk of adverse outcomes for lower lymphocyte counts in patients with lymphopenia. The predictive powers of lymphopenia, expressed as areas under the receiver operating characteristic curves, were 0.68, 0.69, 0.78, and 0.79 for the corresponding adverse outcomes, respectively, after incorporating age, gender, race, and comorbidities. In conclusion, lymphopenia is a useful metric in prognosticating outcomes in hospitalized COVID-19 patients.
- Open Access
- 19 January 2021
- Published by Hindawi Limited in Case Reports in Infectious Diseases
- Vol. 2021, 1-5
COVID-19 Coinfection with Mycobacterium abscessus in a Patient with Multiple Myeloma
Background. Coronavirus disease (COVID-19) is a worldwide pandemic causing multiple fatalities and morbidities worldwide. We report a case of severe pneumonia causing acute respiratory distress syndrome due to a coinfection with SARS-CoV-2 and Mycobacterium abscessus in an elderly patient with multiple myeloma in Florida, USA. Case Presentation. An 84-year-old male with a medical history significant for multiple myeloma not in remission was sent to the emergency department to rule out COVID-19 infection prior to continuing his chemotherapy sessions. At presentation, he had nonspecific mild symptoms and an unremarkable physical examination. He had significant blood test findings including serum lactate dehydrogenase 373 U/L, high sensitive C-reactive protein 17.40 mg/l, and ferritin 415 ng/ml. Xpert-SARS-CoV-2 was positive. Chest radiograph revealed patchy areas of interstitial infiltrates in mid to lower lung zones. During his hospitalization course, his oxygenation deteriorated, requiring mechanical intubation. Repeat chest radiograph showed worsening bilateral infiltrates. He was started on broad-spectrum antibiotics and eventually weaned off mechanical intubation and extubated. On the 11(th) day of admission, he was found to be bradycardic and in shock, and he was reintubated. His labs showed worsening inflammatory markers along with kidney dysfunction to the point of requiring renal replacement therapy. He received both convalescent plasma and remdesivir for treatment of COVID-19 pneumonia. Eventually, repeat blood cultures came back positive for the growth of acid-fast beaded bacilli. While awaiting final culture and sensitivity reports, his antibiotics were upgraded to cover possible nocardia infection. Repeat blood and sputum cultures resulted in growth of AFB bacilli Mycobacterium abscessus 1 week after. Conclusions. This case report highlights the importance of keeping a broad differential and considering multiple coinfections, including atypical ones during this COVID-19 pandemic, such as the one that was discussed above, Mycobacterium abscessus, in order to provide goal-directed therapy.
- 19 January 2021
- Published by Hindawi Limited in Case Reports in Infectious Diseases
- Vol. 2021, 1-5
Open AccessCOVID-19 Coinfection with Mycobacterium abscessus in a Patient with Multiple Myeloma
Background. Coronavirus disease (COVID-19) is a worldwide pandemic causing multiple fatalities and morbidities worldwide. We report a case of severe pneumonia causing acute respiratory distress syndrome due to a coinfection with SARS-CoV-2 and Mycobacterium abscessus in an elderly patient with multiple myeloma in Florida, USA. Case Presentation. An 84-year-old male with a medical history significant for multiple myeloma not in remission was sent to the emergency department to rule out COVID-19 infection prior to continuing his chemotherapy sessions. At presentation, he had nonspecific mild symptoms and an unremarkable physical examination. He had significant blood test findings including serum lactate dehydrogenase 373 U/L, high sensitive C-reactive protein 17.40 mg/l, and ferritin 415 ng/ml. Xpert-SARS-CoV-2 was positive. Chest radiograph revealed patchy areas of interstitial infiltrates in mid to lower lung zones. During his hospitalization course, his oxygenation deteriorated, requiring mechanical intubation. Repeat chest radiograph showed worsening bilateral infiltrates. He was started on broad-spectrum antibiotics and eventually weaned off mechanical intubation and extubated. On the 11(th) day of admission, he was found to be bradycardic and in shock, and he was reintubated. His labs showed worsening inflammatory markers along with kidney dysfunction to the point of requiring renal replacement therapy. He received both convalescent plasma and remdesivir for treatment of COVID-19 pneumonia. Eventually, repeat blood cultures came back positive for the growth of acid-fast beaded bacilli. While awaiting final culture and sensitivity reports, his antibiotics were upgraded to cover possible nocardia infection. Repeat blood and sputum cultures resulted in growth of AFB bacilli Mycobacterium abscessus 1 week after. Conclusions. This case report highlights the importance of keeping a broad differential and considering multiple coinfections, including atypical ones during this COVID-19 pandemic, such as the one that was discussed above, Mycobacterium abscessus, in order to provide goal-directed therapy.